Seattle Genetics initiates Phase I trial of SGN-75
Seattle Genetics announced that it has initiated a phase I clinical trial of SGN-75 for metastatic renal cell carcinoma and relapsed and refractory non-Hodgkin lymphoma. SGN-75 is an antibody-drug conjugate targeting CD70 that utilizes the company’s proprietary technology. :theflyonthewall.com
News For SGEN From The Last 14 Days
Check below for free stories on SGEN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
